{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:30:42Z","timestamp":1790116242854,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Foundation of Administration of Traditional Chinese Medicine of Jiangsu Province","award":["ZD202410"],"award-info":[{"award-number":["ZD202410"]}]},{"name":"Foundation of Administration of Traditional Chinese Medicine of Jiangsu Province","award":["ZD202410"],"award-info":[{"award-number":["ZD202410"]}]},{"name":"Foundation of Administration of Traditional Chinese Medicine of Jiangsu Province","award":["ZD202410"],"award-info":[{"award-number":["ZD202410"]}]},{"name":"Foundation of Administration of Traditional Chinese Medicine of Jiangsu Province","award":["ZD202410"],"award-info":[{"award-number":["ZD202410"]}]},{"name":"Foundation of Administration of Traditional Chinese Medicine of Jiangsu Province","award":["ZD202410"],"award-info":[{"award-number":["ZD202410"]}]},{"name":"Foundation of Administration of Traditional Chinese Medicine of Jiangsu Province","award":["ZD202410"],"award-info":[{"award-number":["ZD202410"]}]},{"name":"Foundation of Administration of Traditional Chinese Medicine of Jiangsu Province","award":["ZD202410"],"award-info":[{"award-number":["ZD202410"]}]},{"name":"Foundation of Administration of Traditional Chinese Medicine of Jiangsu Province","award":["ZD202410"],"award-info":[{"award-number":["ZD202410"]}]},{"name":"Foundation of Administration of Traditional Chinese Medicine of Jiangsu Province","award":["ZD202410"],"award-info":[{"award-number":["ZD202410"]}]},{"name":"Foundation of Administration of Traditional Chinese Medicine of Jiangsu Province","award":["ZD202410"],"award-info":[{"award-number":["ZD202410"]}]},{"name":"Foundation of Administration of Traditional Chinese Medicine of Jiangsu Province","award":["ZD202410"],"award-info":[{"award-number":["ZD202410"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04323-x","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:25:50Z","timestamp":1760081150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ustekinumab trough concentrations predict clinical remission in perianal fistulizing crohn\u2019s disease: a real-world retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaoyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqin","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"1","key":"4323_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn\u2019s disease. Nat Rev Dis Primers. 2020;6(1):22.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"4323_CR2","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1093\/ecco-jcc\/jjab026","volume":"15","author":"B Caron","year":"2021","unstructured":"Caron B, D\u2019Amico F, Danese S, Peyrin-Biroulet L. Endpoints for perianal Crohn\u2019s disease trials: past, present and future. J Crohns Colitis. 2021;15(8):1387\u201398.","journal-title":"J Crohns Colitis"},{"issue":"11","key":"4323_CR3","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nrgastro.2017.104","volume":"14","author":"J Pan\u00e9s","year":"2017","unstructured":"Pan\u00e9s J, Rimola J. Perianal fistulizing Crohn\u2019s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14(11):652\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"4323_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1055\/s-0041-1740038","volume":"35","author":"J Wiseman","year":"2022","unstructured":"Wiseman J, Chawla T, Morin F, de Buck A, Weizman AV. A Multi-Disciplinary approach to perianal fistulizing crohn\u2019s disease. Clin Colon Rectal Surg. 2022;35(1):51\u20137.","journal-title":"Clin Colon Rectal Surg"},{"issue":"5","key":"4323_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jmb.2010.07.046","volume":"402","author":"J Luo","year":"2010","unstructured":"Luo J, Wu SJ, Lacy ER, Orlovsky Y, Baker A, Teplyakov A, Obmolova G, Heavner GA, Richter HT, Benson J. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol. 2010;402(5):797\u2013812.","journal-title":"J Mol Biol"},{"key":"4323_CR6","doi-asserted-by":"crossref","unstructured":"de Rub\u00edn C, Chaparro M, Gisbert JP. Real-world evidence of the effectiveness and safety of ustekinumab for the treatment of crohn\u2019s disease: Systematic Review and Meta-Analysis of Observational Studies. J Clin Med 2022;11(14):4202.","DOI":"10.3390\/jcm11144202"},{"issue":"10342","key":"4323_CR7","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200\u201311.","journal-title":"Lancet"},{"issue":"2","key":"4323_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","volume":"11","author":"P Gionchetti","year":"2017","unstructured":"Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11(2):135\u201349.","journal-title":"J Crohns Colitis"},{"key":"4323_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/JIR.S157358","volume":"11","author":"PG Kotze","year":"2018","unstructured":"Kotze PG, Ma C, Almutairdi A, Panaccione R. Clinical utility of ustekinumab in Crohn\u2019s disease. J Inflamm Res. 2018;11:35\u201347.","journal-title":"J Inflamm Res"},{"issue":"4","key":"4323_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/01.MIB.0000215091.77492.2a","volume":"12","author":"WR Best","year":"2006","unstructured":"Best WR. Predicting the crohn\u2019s disease activity index from the Harvey-Bradshaw index. Inflamm Bowel Dis. 2006;12(4):304\u201310.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"4323_CR11","first-page":"253","volume":"56","author":"Y Wu","year":"2024","unstructured":"Wu Y, Xu Y, Zhang G, Zhang Y, Wang J, You P, et al. Clinical remission and transmural healing of ustekinumab in patients with crohn\u2019s disease. Beijing Da Xue Xue Bao Yi Xue Ban. 2024;56(2):253\u20139.","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"issue":"7","key":"4323_CR12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjz008","volume":"13","author":"B Verstockt","year":"2019","unstructured":"Verstockt B, Dreesen E, Noman M, Outtier A, Van den Berghe N, Aerden I, et al. Ustekinumab exposure-outcome analysis in crohn\u2019s disease only in part explains limited endoscopic remission rates. J Crohns Colitis. 2019;13(7):864\u201372.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"4323_CR13","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.cgh.2019.11.059","volume":"18","author":"OJ Adedokun","year":"2020","unstructured":"Adedokun OJ, Xu Z, Marano C, O\u2019Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, Van Assche G, et al. Ustekinumab pharmacokinetics and exposure response in a phase 3 randomized trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(10):2244\u2013e22552249.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"4323_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1572-0241.2003.07241.x","volume":"98","author":"G Van Assche","year":"2003","unstructured":"Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, D\u2019Hoore A, Penninckx F, Marchal G, Cornillie F, et al. Magnetic resonance imaging of the effects of Infliximab on perianal fistulizing crohn\u2019s disease. Am J Gastroenterol. 2003;98(2):332\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"4323_CR15","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1038\/ajg.2009.509","volume":"104","author":"SC Ng","year":"2009","unstructured":"Ng SC, Plamondon S, Gupta A, Burling D, Swatton A, Vaizey CJ, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for crohn\u2019s perineal fistulas. Am J Gastroenterol. 2009;104(12):2973\u201386.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"4323_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749\u201353.","journal-title":"Gut"},{"issue":"1","key":"4323_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bjs.1800630102","volume":"63","author":"AG Parks","year":"1976","unstructured":"Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg. 1976;63(1):1\u201312.","journal-title":"Br J Surg"},{"issue":"5","key":"4323_CR18","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cgh.2021.09.028","volume":"20","author":"DA Schwartz","year":"2022","unstructured":"Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. Efficacy and safety of 2 Vedolizumab intravenous regimens for perianal fistulizing crohn\u2019s disease: ENTERPRISE study. Clin Gastroenterol Hepatol. 2022;20(5):1059-e10671059.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"23","key":"4323_CR19","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.3748\/wjg.v28.i23.2597","volume":"28","author":"B Gu","year":"2022","unstructured":"Gu B, Venkatesh K, Williams AJ, Ng W, Corte C, Gholamrezaei A, et al. Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal crohn\u2019s disease. World J Gastroenterol. 2022;28(23):2597\u2013608.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"4323_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132(1):52\u201365.","journal-title":"Gastroenterology"},{"issue":"9","key":"4323_CR21","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350(9):876\u201385.","journal-title":"N Engl J Med"},{"issue":"5","key":"4323_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","volume":"52","author":"Y Qiu","year":"2017","unstructured":"Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Chen MH. Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in crohn\u2019s disease. J Gastroenterol. 2017;52(5):535\u201354.","journal-title":"J Gastroenterol"},{"issue":"3","key":"4323_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","volume":"147","author":"BE Sands","year":"2014","unstructured":"Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D\u2019Haens G, Ben-Horin S, Xu J, Rosario M, et al. Effects of Vedolizumab induction therapy for patients with crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618\u2013e627613.","journal-title":"Gastroenterology"},{"issue":"7","key":"4323_CR24","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"JD Feuerstein","year":"2021","unstructured":"Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, Terdiman JP. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing crohn\u2019s disease. Gastroenterology. 2021;160(7):2496\u2013508.","journal-title":"Gastroenterology"},{"issue":"2","key":"4323_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.dld.2021.07.008","volume":"54","author":"L Gonczi","year":"2022","unstructured":"Gonczi L, Szanto K, Farkas K, Molnar T, Szamosi T, Schafer E, et al. Clinical efficacy, drug sustainability and serum drug levels in Crohn\u2019s disease patients treated with ustekinumab - a prospective, multicenter cohort from Hungary. Dig Liver Dis. 2022;54(2):207\u201313.","journal-title":"Dig Liver Dis"},{"key":"4323_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030939","author":"J Yao","year":"2023","unstructured":"Yao J, Zhang H, Su T, Peng X, Zhao J, Liu T, et al. Ustekinumab promotes radiological fistula healing in perianal fistulizing Crohn\u2019s disease: a retrospective real-world analysis. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12030939.","journal-title":"J Clin Med"},{"issue":"2","key":"4323_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.14309\/ajg.0000000000002047","volume":"118","author":"AM Johnson","year":"2023","unstructured":"Johnson AM, Barsky M, Ahmed W, Zullow S, Galati J, Jairath V, et al. The real-world effectiveness and safety of ustekinumab in the treatment of Crohn\u2019s disease: results from the SUCCESS consortium. Am J Gastroenterol. 2023;118(2):317\u201328.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"4323_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/codi.13311","volume":"18","author":"EJ de Groof","year":"2016","unstructured":"de Groof EJ, Sahami S, Lucas C, Ponsioen CY, Bemelman WA, Buskens CJ. Treatment of perianal fistula in Crohn\u2019s disease: a systematic review and meta-analysis comparing Seton drainage and anti-tumour necrosis factor treatment. Colorectal Dis. 2016;18(7):667\u201375.","journal-title":"Colorectal Dis"},{"key":"4323_CR29","doi-asserted-by":"crossref","unstructured":"Inflammatory bowel disease group, chinese society of gastroenterology, chinese medical association, inflammatory bowel disease quality control center of China. 2023 Chinese national clinical practice guideline on diagnosis and management of Crohn's disease. Chin Med J. 2024;137(14):1647\u201350.","DOI":"10.1097\/CM9.0000000000003222"},{"issue":"12","key":"4323_CR30","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10151-023-02765-7","volume":"27","author":"N Fathallah","year":"2023","unstructured":"Fathallah N, Akaffou M, Haouari MA, Spindler L, Alam A, Barr\u00e9 A, et al. Deep remission improves the quality of life of patients with Crohn\u2019s disease and anoperineal fistula treated with darvadstrocel: results of a French pilot study. Tech Coloproctol. 2023;27(12):1201\u201310.","journal-title":"Tech Coloproctol"},{"issue":"4","key":"4323_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1053\/j.gastro.2022.06.052","volume":"163","author":"NH Nguyen","year":"2022","unstructured":"Nguyen NH, Solitano V, Vuyyuru SK, MacDonald JK, Syversen SW, J\u00f8rgensen KK, et al. Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systematic review and meta-analysis. Gastroenterology. 2022;163(4):937-e949932.","journal-title":"Gastroenterology"},{"key":"4323_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071813","author":"M Zulqarnain","year":"2022","unstructured":"Zulqarnain M, Deepak P, Yarur AJ. Therapeutic drug monitoring in perianal fistulizing Crohn\u2019s disease. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11071813.","journal-title":"J Clin Med"},{"issue":"3","key":"4323_CR33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","volume":"153","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827\u201334.","journal-title":"Gastroenterology"},{"key":"4323_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061539","author":"L Bertin","year":"2024","unstructured":"Bertin L, Barberio B, Gubbiotti A, Bertani L, Costa F, Ceccarelli L, et al. Association between ustekinumab trough levels, serum IL-22, and oncostatin M levels and clinical and biochemical outcomes in patients with Crohn\u2019s disease. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13061539.","journal-title":"J Clin Med"},{"issue":"2","key":"4323_CR35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.gtc.2021.12.007","volume":"51","author":"LB Grossberg","year":"2022","unstructured":"Grossberg LB, Cheifetz AS, Papamichael K. Therapeutic drug monitoring of biologics in crohn\u2019s disease. Gastroenterol Clin North Am. 2022;51(2):299\u2013317.","journal-title":"Gastroenterol Clin North Am"},{"issue":"7","key":"4323_CR36","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/ibd\/izae231","volume":"31","author":"R Porth","year":"2025","unstructured":"Porth R, Deyhim T, Geeganage G, Smith B, Zullow S, Rabinowitz LG, et al. Proactive therapeutic drug monitoring of ustekinumab is associated with increased drug persistence in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2025;31(7):1806\u201310.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"4323_CR37","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1007\/s10620-023-07822-7","volume":"68","author":"T Straatmijer","year":"2023","unstructured":"Straatmijer T, Biemans VBC, Moes D, Hoentjen F, Ter Heine R, Maljaars PWJ, Theeuwen R, Pierik M, van der Duijvestein M. Meulen-de Jong AE: ustekinumab trough concentrations are associated with biochemical outcomes in patients with crohn\u2019s disease. Dig Dis Sci. 2023;68(6):2647\u201357.","journal-title":"Dig Dis Sci"},{"issue":"7","key":"4323_CR38","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/ibd\/izac169","volume":"29","author":"E Proietti","year":"2023","unstructured":"Proietti E, Pauwels RWM, van der Woude CJ, Doukas M, Oudijk L, Peppelenbosch MP, Grohmann U, Crombag MBS, de Vries AC, Fuhler GM. Ustekinumab tissue and serum levels in patients with crohn\u2019s disease are closely correlated though not consistently associated with objective response after induction. Inflamm Bowel Dis. 2023;29(7):1038\u201346.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"4323_CR39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12876-022-02271-4","volume":"22","author":"H Hirayama","year":"2022","unstructured":"Hirayama H, Morita Y, Imai T, Takahashi K, Yoshida A, Bamba S, Inatomi O, Andoh A. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with crohn\u2019s disease. BMC Gastroenterol. 2022;22(1):195.","journal-title":"BMC Gastroenterol"},{"issue":"27","key":"4323_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038804","volume":"103","author":"M Shehab","year":"2024","unstructured":"Shehab M, Abdullah I, Alfadhli A, Alrashed F. Relationship between ustekinumab trough concentrations and clinical, biochemical and endoscopic outcomes in crohn\u2019s disease: a multi-center nationwide retrospective study (TARGET STUDY). Medicine. 2024;103(27):e38804.","journal-title":"Medicine"},{"issue":"9","key":"4323_CR41","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/ibd\/izac236","volume":"29","author":"K Chen","year":"2023","unstructured":"Chen K, Chen J, Smith E, Mathani P, Longman R, Lukin D, et al. Serum ustekinumab concentrations are associated with improved outcomes with the magnetic resonance index of activity for crohn\u2019s disease. Inflamm Bowel Dis. 2023;29(9):1499\u2013503.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"4323_CR42","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/apt.17313","volume":"57","author":"S Sethi","year":"2023","unstructured":"Sethi S, Dias S, Kumar A, Blackwell J, Brookes MJ, Segal JP. Meta-analysis: the efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(12):1362\u201374.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"4323_CR43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1590\/s0004-2803.230402023-28","volume":"60","author":"L Rosevics","year":"2023","unstructured":"Rosevics L, Savio MC, Lima Junior E, Ramos Junior O. Fistulizing perianal Crohn\u2019s disease: is the patient\u2019s sex a burden? A systematic review. Arq Gastroenterol. 2023;60(4):490\u2013524.","journal-title":"Arq Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04323-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04323-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04323-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T11:46:39Z","timestamp":1760355999000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04323-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4323"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04323-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Jiangsu Province Hospital of Traditional Chinese Medicine and registered with the Clinical Trial Registry. According to the ethical principles of NHC:\n                      Measures for Guidelines on Ethical Review of Biomedical Research Involving Human Subjects(2023)\n                      , WMA:\n                      Declaration of Helsinki\n                      , and CIOMS:\n                      International Ethical Guidelines for Health-related Research Involving Humans\n                      , the retrospective study is approved and waiver of inform consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final manuscript and the submission to this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"718"}}